Building Your Care Team and Preparing for Visits
At a Glance
For a child with OTULIN-related autoinflammatory syndrome, coordinated care from rheumatology or immunology, genetics, dermatology, and gastroenterology or hepatology is important. Bring genetic, biopsy, symptom, lab, and photo records, and keep a written emergency plan for fever.
Because OTULIN-related autoinflammatory syndrome (ORAS) is an ultra-rare condition that can affect the skin, joints, gut, and liver, care is best provided by a coordinated, multidisciplinary team [1]. Managing this diagnosis effectively requires bringing together specialists who can interpret complex genetic data while actively monitoring your child’s organ health and medication safety [1][2].
Your Core Specialty Team
Ideally, your child’s care should be anchored at a major medical center with expertise in rare autoinflammatory or immunodeficiency diseases [3]. Your core team will likely include:
- Pediatric Rheumatologist or Immunologist: These specialists understand the immune system’s inflammatory pathways and often direct the use of targeted biological therapies like TNF inhibitors [4][5].
- Medical Geneticist and Genetic Counselor: Essential for interpreting your child’s specific OTULIN variants. A genetic counselor will also explain the inheritance pattern (recessive vs. dominant-negative) and provide guidance on family planning and recurrence risks for relatives [1][6].
- Pediatric Dermatologist: Because deep skin nodules (panniculitis) are a hallmark of ORAS, a dermatologist helps monitor skin health and manages wound care [7][8].
- Pediatric Gastroenterologist/Hepatologist: To monitor your child’s gut and liver health through specific lab work and imaging, given the reports of intestinal inflammation and liver abnormalities [9][8].
Depending on your clinic’s structure, a nurse navigator, pharmacist, or social worker may also play a crucial role in coordinating appointments and insurance approvals.
Preparing for the First Specialist Visit
When seeing a new specialist for a rare disease, you are often the primary historian. To make the most of the visit, gather and bring the following “artifacts” (requesting records from your local hospital’s medical records department if necessary):
- The Full Genetic Report: Bring the detailed laboratory report that lists the specific nomenclature of the OTULIN variants, not just a summary note [10][11].
- Biopsy Reports and Slides: If your child had a skin biopsy, request the formal pathology report. The new specialist may want their own pathologist to review the original tissue slides [7].
- A Symptom Timeline: A simple log showing when fevers began, when skin nodules appeared, and patterns in gastrointestinal issues [4][5].
- Growth Charts and Lab Trends: Copies of recent blood work—specifically inflammatory markers and liver enzymes—and a current growth chart [12][9].
- Photo Documentation: High-quality, dated photos of skin nodules or rashes at different stages [8].
Coordinating Care and Emergency Planning
In a multidisciplinary team, you should explicitly identify one specialist to serve as the Lead Clinician or “quarterback” [2]. This physician is responsible for seeing the big picture, reconciling medications, and serving as the primary contact for your local pediatrician [1].
A critical part of care coordination is establishing a written Emergency Action Plan or “travel letter” [13]. Because local emergency departments are unlikely to be familiar with ORAS, this document must be explicitly clear. It should include:
- Your child’s exact diagnosis and baseline health.
- Current medication names, doses, and the date/time of the last dose.
- Allergies and vaccination status.
- Explicit fever and infection instructions: A statement that a fever in an immunosuppressed child requires urgent evaluation for infection and that the ED should not safely assume symptoms are just an ORAS flare [14].
- Direct daytime and after-hours contact numbers for the specialist team.
Organizing this team early ensures that your child’s care is proactive, safe, and built on a foundation of clear communication [15][3].
Common questions in this guide
Which specialists should be on my child’s ORAS care team?
What records should I bring to my child’s first ORAS specialist visit?
Who should coordinate my child’s ORAS care?
What should be included in an ORAS emergency action plan?
Does a fever in a child with ORAS need urgent medical attention?
How can I keep all of my child’s ORAS specialists updated?
Get notified when new evidence is published on autoinflammation, panniculitis, and dermatosis syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Management of Monogenic IL-1 Mediated Autoinflammatory Diseases in Childhood.
Welzel T, Benseler SM, Kuemmerle-Deschner JB
Frontiers in immunology 2021; (12()):516427 doi:10.3389/fimmu.2021.516427.
PMID: 33868220 - 2
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.
Romano M, Arici ZS, Piskin D, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2022; (74(7)):1102-1121 doi:10.1002/art.42139.
PMID: 35621220 - 3
Current Transition Practice for Primary Immunodeficiencies and Autoinflammatory Diseases in Europe: a RITA-ERN Survey.
Israni M, Nicholson B, Mahlaoui N, et al.
Journal of clinical immunology 2023; (43(1)):206-216 doi:10.1007/s10875-022-01345-y.
PMID: 36222999 - 4
Compound heterozygous variants in OTULIN are associated with fulminant atypical late-onset ORAS.
Zinngrebe J, Moepps B, Monecke T, et al.
EMBO molecular medicine 2022; (14(3)):e14901 doi:10.15252/emmm.202114901.
PMID: 35170849 - 5
New data in causes of autoinflammatory diseases.
Kone-Paut I, Georgin-Laviallec S, Galeotti C, et al.
Joint bone spine 2019; (86(5)):554-561 doi:10.1016/j.jbspin.2018.11.003.
PMID: 30471422 - 6
Current genetic diagnostics in inborn errors of immunity.
von Hardenberg S, Klefenz I, Steinemann D, et al.
Frontiers in pediatrics 2024; (12()):1279112 doi:10.3389/fped.2024.1279112.
PMID: 38659694 - 7
Vasculitis in Systemic Autoinflammatory Diseases.
Demir S, Sag E, Dedeoglu F, Ozen S
Frontiers in pediatrics 2018; (6()):377 doi:10.3389/fped.2018.00377.
PMID: 30560109 - 8
OTULIN deficiency in ORAS causes cell type-specific LUBAC degradation, dysregulated TNF signalling and cell death.
Damgaard RB, Elliott PR, Swatek KN, et al.
EMBO molecular medicine 2019; (11(3)) doi:10.15252/emmm.201809324.
PMID: 30804083 - 9
OTULIN protects the liver against cell death, inflammation, fibrosis, and cancer.
Damgaard RB, Jolin HE, Allison MED, et al.
Cell death and differentiation 2020; (27(5)):1457-1474 doi:10.1038/s41418-020-0532-1.
PMID: 32231246 - 10
OTULIN-related conditions: Report of a new case and review of the literature using GenIA.
Caballero-Oteyza A, Crisponi L, Peng XP, et al.
Research square 2024; doi:10.21203/rs.3.rs-3950863/v2.
PMID: 38712244 - 11
A de novo dominant-negative variant is associated with OTULIN-related autoinflammatory syndrome.
Takeda Y, Ueki M, Matsuhiro J, et al.
The Journal of experimental medicine 2024; (221(6)) doi:10.1084/jem.20231941.
PMID: 38652464 - 12
Screening of OTULIN gene mutation with targeted next generation sequencing in Turkish populations and in silico analysis of these mutations.
Gezgin Y, Kırnaz B, Berdeli A
Molecular biology reports 2022; (49(6)):4643-4652 doi:10.1007/s11033-022-07312-5.
PMID: 35294702 - 13
[Transition from pediatric to adult care: Recommendations of the French network for autoimmune and autoinflammatory diseases (FAI2R)].
Georgin-Lavialle S, Hentgen V, Truchetet ME, et al.
La Revue de medecine interne 2021; (42(9)):633-638 doi:10.1016/j.revmed.2021.02.003.
PMID: 34147259 - 14
The Deubiquitinase OTULIN Is an Essential Negative Regulator of Inflammation and Autoimmunity.
Damgaard RB, Walker JA, Marco-Casanova P, et al.
Cell 2016; (166(5)):1215-1230.e20 doi:10.1016/j.cell.2016.07.019.
PMID: 27523608 - 15
Transition to Adult Care in Autoinflammatory Diseases: A Cohort of 111 French Patients.
Elhani I, Hentgen V, Quartier P, et al.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2024; (30(7)):297-299 doi:10.1097/RHU.0000000000002132.
PMID: 39186594
This page is for informational purposes only and does not constitute medical advice. Your child’s ORAS specialists should provide individualized guidance, including what to do about fever, infection concerns, and medication changes.